과학 일러스트 스튜디오. 엄밀한 첨단 메커니즘을 출판 등급의 논문 삽화로 구현합니다.

tumor cells, CD8+ T cells, TAM macrophages, the PD-1/PD-L1 immune checkpoint, anti-PD-1 therapy, cytotoxic killing, and tumor apoptosis as one coherent causal story

intravenous LNP delivery, cellular uptake, endosomal acidification, ionizable-lipid protonation, membrane fusion, mRNA release, ribosomal translation, and target protein expression

patient samples, tissue dissociation, scRNA-seq and scATAC-seq, cell clustering, lineage states, regulatory networks, resistant subpopulations, and clinical associations

dietary fiber, gut microbiota, short-chain fatty acids, intestinal barrier, circulation, blood-brain barrier, microglial state, and neuroinflammatory outcomes

target DNA, sgRNA, Cas9 nickase, deaminase, target base conversion, mismatch repair, bystander-edit control, and functional rescue

visible-light excitation, heterojunction band alignment, electron-hole separation, interfacial transfer, HER hydrogen evolution, OER oxygen evolution, and surface active sites

proximal-tubule SGLT2 inhibition, glucosuria and natriuresis, reduced volume load, improved myocardial energetics, lower oxidative stress, and attenuated ventricular remodeling

CAR architecture, tumor-antigen recognition, immune synapse, CD3-zeta and costimulatory signaling, granzyme B/perforin release, Fas-FasL, and tumor-cell apoptosis

fatty-acid overload, mitochondrial stress, ROS, hepatocyte injury, Kupffer-cell activation, inflammatory cytokines, hepatic-stellate-cell activation, collagen deposition, and fibrosis

GLP-1R binding, Gs protein, adenylyl cyclase, cAMP, PKA/Epac2, KATP channels, membrane depolarization, calcium influx, and insulin-vesicle exocytosis

bispecific antibody binding CD3 and a tumor antigen, immune-synapse formation, T-cell activation, cytotoxic-granule release, tumor-cell lysis, and cytokine feedback

System Xc-minus, glutathione synthesis, GPX4, PUFA-phospholipids, ACSL4, labile iron pool, Fenton chemistry, lipid ROS accumulation, and membrane failure

growth factor, RTK, PI3K, PIP3, AKT, TSC1/2, mTORC1, S6K, 4E-BP1, and proliferation/protein-synthesis outputs

hypoxia, PHD/VHL suppression, HIF-1alpha stabilization, nuclear translocation, HRE binding, GLUT1/LDHA/VEGFA transcription, glycolysis, and angiogenesis

DNA damage, ATM/ATR, CHK1/2, p53 stabilization, p21 cell-cycle arrest, BAX/PUMA apoptosis, and recovery after repair

TGF-beta ligand, TGFBR2/TGFBR1 complex, SMAD2/3 phosphorylation, SMAD4 binding, nuclear translocation, and EMT-related gene expression

tumor cells, cancer-associated fibroblasts, IL-6 secretion, IL6R/gp130, JAK-STAT3, ECM remodeling, immunosuppression, invasion, and bidirectional feedback

Wnt receptors, beta-catenin stabilization, YAP/TAZ nuclear translocation, TEAD, shared target genes, stemness, proliferation, and positive/negative crosstalk nodes

apical and basolateral hepatocyte polarity, bile canalicular lumen, tight junctions, bile-salt transporters, sinusoid, and transport directions

outer membrane, inner membrane, cristae, intermembrane space, matrix, complexes I-IV, ATP synthase, proton gradient, and ATP-production direction

tumor core, invasive margin, vessels, hypoxic region, CAFs, T cells, macrophages, ECM, and their spatial relationships

Fab, Fc, heavy chain, light chain, hinge, disulfide bonds, antigen-binding sites, and bispecific engineering junctions

inorganic core, polymer shell, PEG, targeting ligand, loaded drug, pH-responsive linker, size annotation, and release direction

inlet, serpentine mixer, cell-focusing channel, capture chambers, valves, outlet, flow direction, and key dimensional hierarchy

patient tissue collection, digestion, organoid culture, expansion, dose-gradient treatment, viability assay, imaging, sensitivity scoring, and candidate selection

study centers, recruitment, baseline assessment, exposure stratification, follow-up points, primary endpoint, loss-to-follow-up handling, statistical analysis, and sensitivity analysis

sgRNA design, vector construction, transfection, selection, single-clone isolation, genotyping, Western blot, and functional validation

cell preparation, orthotopic implantation, randomization, dosing time points, tumor monitoring, endpoint definition, tissue collection, immunohistochemistry, and survival analysis

blood collection, cell-removal centrifugation, SEC or ultracentrifugation, exosome validation, lysis, protein quantification, digestion, desalting, LC-MS/MS, and database search

Day 0 implantation, tumor-threshold trigger, randomization, fractionated radiotherapy, anti-PD-1 dosing, serial blood collection, imaging, endpoint sampling, and long-term survival follow-up

eligibility assessment, exclusion reasons, randomization, intervention and control arms, loss to follow-up, discontinuation, analyzed populations, and clear N placeholders

diagnosed patients, tissue/liquid biopsy, NGS testing, actionable-variant decision, molecular tumor board, matched trial, unmatched cohort, and follow-up

screening, washout, 1:1 randomization, treatment arm, placebo arm, blinding, primary endpoint, secondary endpoints, safety follow-up, and analysis sets

nodule size and morphology, patient risk factors, low-dose CT follow-up, PET-CT, biopsy/bronchoscopy, surgical evaluation, and benign/malignant outcomes

early versus metastatic stratification, neoadjuvant therapy, surgery, pCR decision, adjuvant regimen, sequential anti-HER2 therapy after recurrence, and brain-metastasis branch

HFrEF/HFmrEF/HFpEF, NT-proBNP level, renal function, atrial fibrillation, diabetes, congestion status, risk level, and treatment priority

FASTQ QC, adapter trimming, alignment, count matrix, normalization, differential analysis, volcano/heatmap outputs, GO/KEGG/GSEA, and candidate validation

tissue dissociation, single-cell capture, library sequencing, QC, doublet removal, normalization, dimensionality reduction, clustering, marker calling, cell annotation, and differential-state analysis

tissue sectioning, H&E imaging, spatial capture, sequencing, spot QC, spatial clustering, region annotation, cell-type deconvolution, and spatial ligand-receptor analysis

three omics inputs, per-omics QC and differential analysis, ID mapping, batch correction, correlation networks, pathway-level integration, latent-factor modeling, and biomarker candidates

EHR, imaging and omics inputs, missing-data handling, feature engineering, train-validation-test split, cross-validation, model comparison, SHAP explanation, external validation, and deployment

WSI slides, tissue detection, patching, stain normalization, feature encoding, MIL aggregation, classification/prognosis task, internal validation, external cohort, and interpretability heatmaps

x-axis log2 fold change, y-axis -log10 adjusted P, distinct significant up/down colors, threshold guide lines, labels for top genes, and a concise legend

genes as rows, samples as columns, z-score scale, hierarchical dendrograms, sample-group annotation bars, highlighted gene modules, and concise legends

2D UMAP embedding, major cell types in distinct colors, clear cluster boundaries, representative marker labels, and a small companion panel for patient/condition source

time axis, PFS probability, two step curves, censor marks, number-at-risk table, HR with 95% CI, and appropriately placed log-rank P value

subgroup labels, sample sizes, HR/OR point estimates with 95% CI, null line, overall-effect diamond, interaction P values, and left/right benefit direction

first-line, second-line and third-line treatments, response/progression/discontinuation outcomes, link widths proportional to patient counts, nodes grouped by treatment class, and N labels